50
Participants
Start Date
April 30, 2008
Primary Completion Date
October 31, 2016
Study Completion Date
October 31, 2016
Docetaxel
Docetaxel at the dose of 75 mg/m2 IV on days 1 every 3 weeks for 6 consecutive cycles.
Bevacizumab
Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks for 6 cycles
University Hospital of Heraklion, Heraklion
University General Hospital of Alexandroupolis, Dep of Medical Oncology, Alexandroupoli
"Laikon General Hospital, Medical Oncology Unit, Propedeutic Dep of Internal Medicine", Athens
401 Military Hospital, Medical Oncology Unit, Athens
Air Forces Military Hospital, Dep of Medical Oncology, Athens
"IASO General Hospital of Athens, 1st Dep of Medical Oncology", Athens
Sismanogleio General Hospital, 1st, 2nd Dep of Pulmonary Diseases, Athens
"Sotiria General Hospital, 1st, 3rd, 8th Dep of Pulmonary Diseases", Athens
"Metaxa's Anticancer Hospital of Piraeus,1st Dep of Medical Oncology", Piraeus
"Theagenion Anticancer Hospital of Thessaloniki", Thessaloniki
Lead Sponsor
Hellenic Oncology Research Group
OTHER